Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Non-cash Items (2019 - 2022)

C4 Therapeutics' Non-cash Items history spans 4 years, with the latest figure at $1.7 million for Q1 2022.

  • For Q1 2022, Non-cash Items rose 214.0% year-over-year to $1.7 million; the TTM value through Mar 2022 reached $1.7 million, up 214.0%, while the annual FY2021 figure was $1.4 million, 199.03% up from the prior year.
  • Non-cash Items reached $1.7 million in Q1 2022 per CCCC's latest filing, up from $1.4 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $102.6 million in Q4 2020 to a low of $531248.0 in Q1 2021.
  • Average Non-cash Items over 4 years is $15.6 million, with a median of $1.5 million recorded in 2021.
  • Peak YoY movement for Non-cash Items: soared 2037.78% in 2020, then tumbled 98.67% in 2021.
  • A 4-year view of Non-cash Items shows it stood at $4.8 million in 2019, then skyrocketed by 2037.78% to $102.6 million in 2020, then crashed by 98.67% to $1.4 million in 2021, then increased by 22.43% to $1.7 million in 2022.
  • Per Business Quant, the three most recent readings for CCCC's Non-cash Items are $1.7 million (Q1 2022), $1.4 million (Q4 2021), and $1.1 million (Q3 2021).